SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
1 Year Est. Return
+115.63%
AUM
$2.47B
AUM Growth
+$112M
(+4.7%)
Holding
119
Top Buys
| 1 | +$104M | |
| 2 | +$63.4M | |
| 3 | +$63.3M | |
| 4 |
Krystal Biotech
KRYS
|
+$56.4M |
| 5 |
Progyny
PGNY
|
+$44.3M |
Top Sells
| 1 | +$80.6M | |
| 2 | +$74.2M | |
| 3 | +$57.1M | |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$39M |
| 5 |
GSK
GSK
|
+$31.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Kodiak Sciences
KOD
$2.14B
| – | – |
-60,000
|
|
||
102
Madrigal Pharmaceuticals
MDGL
$11.3B
| – | – |
-500
|
|
||
103
MoonLake Immunotherapeutics
MLTX
$1.34B
| – | – |
-400,000
|
|
||
104
Neurocrine Biosciences
NBIX
$16.6B
| – | – |
-175,982
|
|
||
|
GRAL
105
GRAIL Inc
GRAL
$2.62B
| – | – |
-11,000
|
|
||
|
BCAX
106
Bicara Therapeutics
BCAX
$1.31B
| – | – |
-100,000
|
|
||
|
ABVX
107
Abivax
ABVX
$8.36B
| – | – |
-45,000
|
|
||
|
ACLX
108
DELISTED
Arcellx
ACLX
| – | – |
-30,000
|
|
||
|
BLTE
109
Belite Bio
BLTE
$5.5B
| – | – |
-40,354
|
|
||
110
CalciMedica
CALC
$13.4M
| – | – |
-683,904
|
|
||
111
Olema Pharmaceuticals
OLMA
$918M
| – | – |
-69,874
|
|
||
112
QuidelOrtho
QDEL
$927M
| – | – |
-75,000
|
|
||
|
RAPT
113
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-764,000
|
|
||
|
TERN
114
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-212,710
|
|
||
115
Teleflex
TFX
$5.69B
| – | – |
-190,000
|
|
||
116
Tenet Healthcare
THC
$14.2B
| – | – |
-92,500
|
|
||
117
Viking Therapeutics
VKTX
$3.46B
| – | – |
-70,000
|
|
||
118
State Street SPDR S&P Biotech ETF
XBI
$8.12B
| – | – |
0
|
|
||
119
Fractyl Health
GUTS
$116M
| – | – |
-400,000
|
|